Heavy metal poisoning

disease
On this page

Also known as chronic heavy metal poisoningheavy metal toxicitytoxic effect of heavy metal

Summary

Heavy metal poisoning (MONDO:0023305) is a disease with 1 GWAS associations across 1 studies and 4 clinical trials. Top therapeutic interventions include edetate calcium disodium monohydrate. A subtype of poisoning — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • GWAS associations: 1
  • Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameheavy metal poisoning
Mondo IDMONDO:0023305
EFOEFO:1001518
MeSHD000075322
SNOMED CT85866007
GARD0006577
NORD1219
Is cancer (heuristic)no

Also known as: chronic heavy metal poisoning · heavy metal poisoning · heavy metal toxicity · toxic effect of heavy metal

Data availability: 1 GWAS association (1 study).

Disease family

This is a subtype of poisoning. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › poisoningheavy metal poisoning

Related subtypes (58): toxic oil syndrome, infantile mercury poisoning, ketamine-induced biliary dilatation, manganese poisoning, cyanide-induced parkinsonism, colchicine poisoning, methanol poisoning, ethylene glycol poisoning, paraquat poisoning, lead poisoning, mercury poisoning, acute opioid poisoning, acute tricyclic antidepressant poisoning, acute poisoning by drugs with membrane-stabilizing effect, snakebite envenomation, paracetamol poisoning, cyanide poisoning, scorpion envenomation, argyria, acute ackee fruit intoxication, cocaine intoxication, systemic monochloroacetate poisoning, water intoxication, cassavism, formaldehyde poisoning, abacavir toxicity, allopurinol toxicity, codeine toxicity, efavirenz toxicity, flucloxacilline toxicity, isoniazid toxicity, raltegravir toxicity, voriconazole toxicity, curariform drugs toxicity, statin toxicity, phenytoin or carbamazepine toxicity, letrozole toxicity, ricin poisoning, ivermectin toxicity, belinostat toxicity or dose selection, toxicity to dolutegravir, mycotoxicosis, ciguatera fish poisoning, lathyrism, cadmium poisoning, phenytoin toxicity, nerve agent poisoning, local anesthetic poisoning, fire ant poisoning, aflatoxicosis, black widow spider envenomation, platinum-induced ototoxicity, carbon monoxide poisoning, organophosphate poisoning, sulfur mustard poisoning, cardiac glycoside intoxication, monochloroacetic acid poisoning, chemotherapy-induced toxicity

Subtypes (3): thallium poisoning, cesium poisoning, iron poisoning

Genetics & variants

GWAS landscape

1 GWAS associations across 1 studies. Top hits map to 1 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs1390798312e-11B3GAT1-DT?

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90651243Liu TY202593236,141Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding0
Tier 2: splice/UTR0
Tier 3: regulatory0
Tier 4: intronic/intergenic1

MAF distribution

BucketVariants
common (>=0.05)0
low_freq (0.01-0.05)0
rare (<0.01)0
unknown1

Functional consequences

ConsequenceCount
intron_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs13907983111134524977G>Aintron_variantB3GAT1-DT2e-11Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Ferrous Sulfate, Folic Acid, Propylene Glycol, Salicylic Acid, Vitamin E.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified3
PHASE41

Top trials by phase / activity

NCTPhaseStatusTitle
NCT02421029PHASE4WITHDRAWNProlonged Gadolinium Retention After MRI Imaging
NCT02159235Not specifiedCOMPLETEDHeavy Metals, Angiogenesis Factors and Osteopontin in Coronary Artery Disease (CAD)
NCT03332706Not specifiedUNKNOWNthe Association Between Blood’s and Urinary Heavy Metal Level in Pregnant Women and the Spontaneous Abortion
NCT03693079Not specifiedCOMPLETEDInvestigation of Wet Cupping Therapy on Heavy Metal Levels of Steel Industry Workers

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
EDETATE CALCIUM DISODIUM MONOHYDRATE41